Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2018

14 - 17 Jun 2018

Stockholmsmässan, Stockholm, Sweden

EHA 23: Results of OPTIMISMM study show triplet combination improved PFS in early lines of r/r MM

EHA 23: Results of OPTIMISMM study show triplet combination improved PFS in early lines of r/r MM

$EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML$

EHA 23: Quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

EHA 23: JAK inhibitors associated with aggressive lymphoma

EHA 23: JAK inhibitors associated with aggressive lymphoma

More from ecancer